<DOC>
	<DOCNO>NCT01112306</DOCNO>
	<brief_summary>Long-term , single-arm , multicenter , open-label extension , Phase 3 study , evaluate safety tolerability ACT-293987 patient PAH participate double-blind study AC-065A302 ( GRIPHON )</brief_summary>
	<brief_title>ACT-293987 Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Patients participate doubleblind study AC065A302 either morbidity event complete study schedule per protocol . Signed informed consent . Patients start receive prostacyclin ( epoprostenol ) prostacyclin analog ( i.e. , treprostinil , iloprost , beraprost ) since last study drug intake AC065A302/GRIPHON . Severe hepatic impairment ( ChildPugh C ) . Females pregnant plan become pregnant study , breastfeed . Any known factor disease might interfere treatment compliance , study conduct interpretation result , drug alcohol dependence , psychiatric disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Open-label</keyword>
	<keyword>PAH</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>